Curaleaf Holdings has launched an unsolicited takeover bid for Canadian rival Aurora Cannabis, a move poised to significantly consolidate and reshape the competitive landscape of the international medical cannabis sector, particularly within Europe. This strategic acquisition aims to combine the companies’ substantial European footprints and cultivation capabilities, signalling a decisive shift towards international markets as North American growth matures.
Curaleaf’s Unsolicited Bid Targets European Dominance
In a significant development for the global cannabis industry, Curaleaf Holdings, a leading international cannabis company, announced its intention to acquire Aurora Cannabis through an unsolicited takeover bid. The offer, made public on August 11, seeks to purchase all outstanding shares of Aurora at a price of US$4.00 per share. This proposed transaction, valued at approximately US$236 million on a basic-share basis, represents a 45% premium over Aurora’s 30-day volume-weighted average price of US$2.75.
Curaleaf Chairman and CEO Boris Jordan stated that this combination would benefit both Curaleaf and Aurora shareholders. However, Aurora Cannabis responded cautiously, disputing Curaleaf’s account of prior private discussions and confirming its board would establish a special committee of independent directors to evaluate the proposal. This marks a rare ‘hostile’ approach in the cannabis sector, reminiscent of Green Growth Brands’ unsuccessful bid for Aphria in 2019.
The Valuation Landscape: A Maturing Market
The proposed US$236 million valuation for Aurora stands in stark contrast to the multi-billion dollar deals that characterised the initial ‘green rush’ era. For instance, Aphria’s 2020 merger with Tilray was valued at roughly US$3.9 billion, and Aurora’s own 2018 acquisition of MedReleaf was reported between US$2.5 billion and US$3.2 billion. Curaleaf’s 2020 purchase of Grassroots also exceeded US$875 million.
This shift in valuation reflects a maturing industry. While Aurora’s MedReleaf acquisition in 2018 priced the target at approximately 66 times its projected revenue, Curaleaf’s current offer values Aurora at close to 1x its fiscal 2026 revenue of CA$320.6 million (converted at roughly CA$1.40 to the US dollar). Industry observers like Sean McLean, CEO of PPS, argue that the cannabis sector is artificially suppressed and anticipates a structural repricing as regulatory constraints ease. Others, such as Philip Campbell, CEO of Herbal Dispatch, suggest this reflects increased investor discipline and caution following lessons learned from the sector’s early exuberance.
Europe: The Crucial Battleground for Growth
The strategic significance of Curaleaf’s bid is deeply rooted in the companies’ respective European operations. As North American consumer cannabis markets become increasingly competitive and commoditised, Europe’s more stringently regulated medical cannabis markets are experiencing rapid growth. Forecasts from Prohibition Partners suggest medical cannabis sales in Europe could more than double by 2028.
Aurora Cannabis has been an early and aggressive mover in the European market. In its fiscal 2026 Q3 results, the Edmonton-based producer reported record global medical cannabis net revenue of CA$76.2 million for the quarter, a 12% year-on-year increase, primarily driven by strong performance in Germany and Poland. Medical operations accounted for 81% of its revenue and 95% of adjusted gross profit in that quarter, rising to 91% of total revenue for the full year. Aurora confirmed its intention to exit Canadian consumer cannabis markets from Q4 FY26 onwards to focus on international medical cannabis, citing stronger margins and growth potential. This strategic pivot included the divestiture of its 50.1% stake in plant propagation unit Bevo in February 2026 and securing EU Community Plant Variety Rights for two proprietary strains across all 27 EU member states.
Aurora’s European assets include its German business, Pedanios, which boasts EU-GMP certified manufacturing capacity and launched localised digital platforms in Germany, the UK, and Poland in February 2026. During its Q1 2027 earnings call, Aurora’s CEO, Miguel Martin, highlighted the company’s number one market share in Poland and noted two of its proprietary cultivars consistently rank in the top five by sales in Germany, where Aurora is one of only three active in-country producers with both production and research and development licenses.
Curaleaf’s Expanding International Footprint
Curaleaf’s own international division is also a critical component of its growth strategy, helping to offset “double-digit domestic price compression” in North America. While Curaleaf recorded full-year 2025 revenue of US$1.27 billion, its international arm, Curaleaf International, posted US$172.5 million in revenue for the year, marking a robust 63% increase. Q4 alone saw a 65% year-on-year rise, putting its annualised run rate above US$200 million.
The growth was primarily driven by its operations in Germany, where Curaleaf is the largest single supplier of cannabis flower, and the UK, where its Curaleaf Clinic held the top market share by patient count during the quarter. Beyond flower exports, Curaleaf’s CE-certified QMID inhalation device, the first of its kind in the UK, is seen as a key differentiator, especially as France and Spain develop medical cannabis frameworks favouring standardised, device-led delivery systems. Curaleaf also operates EU-GMP facilities in Portugal, Spain, and Canada.
Despite strong international growth, Curaleaf reported a full-year net loss of US$228 million, with its international arm currently impacting group EBITDA margins. New markets in France and Turkey are anticipated to come online in late 2026 and early 2027, respectively, further expanding its global reach. In February, Curaleaf completed a US$500 million private placement of senior secured notes, described by CEO Boris Jordan as the largest bond offering in the cannabis sector, indicating growing institutional investor interest. This refinancing provided Curaleaf with US$102 million in cash, giving it the flexibility to pursue strategic acquisitions like the bid for Aurora.
Synergies and Future Market Consolidation
Boris Jordan articulated the rationale behind the takeover bid, suggesting that combining “Curaleaf’s global distribution platform with Aurora’s leading international medical cannabis franchise and EU-GMP cultivation and manufacturing capacity” would unlock significant cost and revenue synergies, estimated at a minimum of US$40 million annually. The pro forma combined entity would boast a trailing 12-month revenue of US$1.5 billion and adjusted EBITDA of US$350 million, with operations spanning 17 countries.
In Europe, this merger would not merely create a new position but rather consolidate two already strong presences. Aurora’s leading market share in Poland, its EU-GMP manufacturing through Pedanios, and cultivation capacity would complement Curaleaf’s status as Germany’s largest flower supplier, its UK clinic network, and its own EU-GMP facilities. Together, the companies would hold either outright leadership or a top-five product position in three of Europe’s most closely watched medical cannabis markets.
This bid underscores a broader trend of consolidation within the global cannabis industry, driven by the search for profitability and market share in increasingly competitive environments. The focus on Europe highlights the region’s potential as a growth engine for medical cannabis, with companies strategically aligning to capitalise on evolving regulatory landscapes and patient access. Business of Cannabis reported on August 14, 2026, that Aurora’s shares rose 22% to US$3.48 following the announcement.
“We believe this combination represents a win-win for Curaleaf and Aurora shareholders,” said Boris Jordan, Chairman and Chief Executive Officer of Curaleaf, regarding the offer.
The outcome of Curaleaf’s bid for Aurora will be closely watched, as it could set a precedent for future M&A activity in the global cannabis market, particularly as companies seek to solidify their positions in burgeoning international medical cannabis economies. Readers are reminded to verify current regulations in their respective jurisdictions, as cannabis laws vary significantly worldwide.
For more insights into global cannabis policy shifts, explore our article on the UN Report: Global Cannabis Use Up 40%, Policy Shifts and Market Dynamics. Additionally, learn more about strategies in specific European markets by reading about Releaf Clinic UK: Medical Cannabis & Healthcare Reform.
Frequently Asked Questions
What is Curaleaf’s offer for Aurora Cannabis?
Curaleaf has made an unsolicited offer to purchase all outstanding shares of Aurora Cannabis at US$4.00 per share, comprising 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share.
Why is Europe central to this acquisition bid?
Europe’s rapidly growing medical cannabis markets offer significant growth opportunities, contrasting with the maturing North American consumer market. Both Curaleaf and Aurora have established strong presences in key European countries.
What are the stated benefits of a combined Curaleaf and Aurora?
Curaleaf projects substantial cost and revenue synergies, estimated at a minimum of US$40 million annually, by combining their global distribution platforms, international medical cannabis franchises, and EU-GMP cultivation capacities.
How does this bid compare to earlier cannabis industry acquisitions?
The current US$236 million valuation for Aurora is significantly lower than multi-billion dollar deals seen during the initial ‘green rush’ era, reflecting a more disciplined and cautious investment climate in a maturing sector.
What is Aurora Cannabis’s response to the offer?
Aurora Cannabis has responded cautiously, disputing Curaleaf’s account of private dealings and announcing that its board will form a special committee of independent directors to evaluate the proposal.
Which European countries are key to the combined entity’s strategy?
Key European markets include Germany, where Curaleaf is a major supplier, and Poland, where Aurora holds a leading market share. The UK also represents a significant market for both companies, alongside other EU nations.
